[go: up one dir, main page]

WO2008155918A1 - RÉGULATION DE HIF-1 PAR MT1-MMP, iFIH ET FIH-1 - Google Patents

RÉGULATION DE HIF-1 PAR MT1-MMP, iFIH ET FIH-1 Download PDF

Info

Publication number
WO2008155918A1
WO2008155918A1 PCT/JP2008/001593 JP2008001593W WO2008155918A1 WO 2008155918 A1 WO2008155918 A1 WO 2008155918A1 JP 2008001593 W JP2008001593 W JP 2008001593W WO 2008155918 A1 WO2008155918 A1 WO 2008155918A1
Authority
WO
WIPO (PCT)
Prior art keywords
ifih
mmp
hif
fih
regulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/001593
Other languages
English (en)
Japanese (ja)
Inventor
Motoharu Seiki
Takeharu Sakamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Publication of WO2008155918A1 publication Critical patent/WO2008155918A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Abstract

La présente invention a pour objet un procédé de promotion ou d'inhibition de l'activité de HIF-1 et un procédé de criblage à la recherche d'un composé capable de favoriser ou d'inhiber l'activité de HIF-1. A savoir, un procédé de promotion ou d'inhibition de l'activité de HIF-1α par l'amplification ou l'abaissement de l'interaction entre la protéine FHI-1 et la protéine iFIH ou MT1-MMP-CP; et un procédé de criblage à la recherche d'un composé capable de favoriser ou d'inhiber l'activité de HIF-1 en recherchant un composé capable d'amplifier ou d'abaisser l'interaction entre la protéine FHI-1 et la protéine iFIH ou MT1-MMP-CP.
PCT/JP2008/001593 2007-06-20 2008-06-20 RÉGULATION DE HIF-1 PAR MT1-MMP, iFIH ET FIH-1 Ceased WO2008155918A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-162272 2007-06-20
JP2007162272A JP2010195684A (ja) 2007-06-20 2007-06-20 ＭＴＩ−ＭＭＰ、ｉＦＩＨ、ＦＩＨ−１によるＨＩＦ−１の制御

Publications (1)

Publication Number Publication Date
WO2008155918A1 true WO2008155918A1 (fr) 2008-12-24

Family

ID=40156082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001593 Ceased WO2008155918A1 (fr) 2007-06-20 2008-06-20 RÉGULATION DE HIF-1 PAR MT1-MMP, iFIH ET FIH-1

Country Status (2)

Country Link
JP (1) JP2010195684A (fr)
WO (1) WO2008155918A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012026614A1 (fr) * 2010-08-24 2012-03-01 国立大学法人宮崎大学 Composition supprimant une activité de métalloprotéinase de matrice
JP2016029375A (ja) * 2013-02-13 2016-03-03 国立大学法人 東京大学 がんの検査方法及び検査用キット

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240352533A1 (en) * 2023-04-24 2024-10-24 Nantbio, Inc. Monocarboxylic Acid Transporter 4 as a Biomarker for Hypoxia Driven Tumor Growth and Treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BANERJI B. ET AL.: "The inhibition of factor inhibiting hypoxia-inducible factor (FIH) by beta-oxocarboxylic acids", CHEMICAL COMMUNICATIONS (CAMBRIDGE, UNITED KINGDOM, no. 43, 2005, pages 5438 - 5440 *
DATTA K. ET AL.: "Protein Kinase C zbeta Transactivates Hypoxia-Inducible Factor alpha by Promoting Its Association with p300 in Renal Cancer", CANCER RESEARCH, vol. 64, 2004, pages 456 - 462 *
HEWITSON K.S. ET AL.: "Hypoxia-inducible Factor (HIF) Asparagine Hydroxylase Is Identical to Factor Inhibiting HIF (FIH) and Is Related to the Cupin Structural Family", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 29, 2002, pages 26351 - 26355, XP002254661 *
UEKITA T. ET AL.: "Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity", THE JOURNAL OF CELL BIOLOGY, vol. 155, no. 7, 2001, pages 1345 - 1356 *
UEKITA T. ET AL.: "Membrane-type 1 Matrix Metalloproteinase Cytoplasmic Tail-binding Protein-1 Is a New Member of the Cupin Superfamily", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 13, 2004, pages 12734 - 12743 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012026614A1 (fr) * 2010-08-24 2012-03-01 国立大学法人宮崎大学 Composition supprimant une activité de métalloprotéinase de matrice
JP5888746B2 (ja) * 2010-08-24 2016-03-22 国立大学法人 宮崎大学 マトリックスメタロプロテアーゼ活性抑制組成物
JP2016029375A (ja) * 2013-02-13 2016-03-03 国立大学法人 東京大学 がんの検査方法及び検査用キット

Also Published As

Publication number Publication date
JP2010195684A (ja) 2010-09-09

Similar Documents

Publication Publication Date Title
WO2006092213A8 (fr) Pyrazolylcarboxanilides
WO2008112199A8 (fr) Procédé d'inhibition de la topoisomérase ii
WO2009048101A1 (fr) Composé amide
WO2006015159A3 (fr) Inhibiteurs de canal a potassium
WO2005108358A3 (fr) Inhibiteurs de la bace
WO2007101225A3 (fr) Procedes permettant d'identifier les inhibiteurs de reponse aux proteines depliees
WO2013091897A8 (fr) Combinaison d'un composé ayant l'aptitude à réarranger une enzyme lysosomale et d'ambroxol et/ou d'un dérivé d'ambroxol
WO2009016257A3 (fr) Procédé de production d'une boisson lactée acidifiée
NO20082298L (no) Kaliumkanalinhibitorer
WO2008110280A3 (fr) Phénoxyphénylamidines 3-substituées et leur utilisation comme fongicides
FR2910230B3 (fr) Methodes de biofertilisations pour ameliorer la stabilite des rendements de grandes cultures agronomiques.
WO2006039250A3 (fr) Sels de compose heterocyclique se liant aux chimiokines et procedes d'utilisation correspondants
WO2007140390A3 (fr) Procédé de modulation de la pousse des cheveux
WO2007050348A3 (fr) Inhibiteurs du canal potassique
WO2008155918A1 (fr) RÉGULATION DE HIF-1 PAR MT1-MMP, iFIH ET FIH-1
WO2007062314A3 (fr) Inhibiteurs de cetp heterocycliques
WO2006012594A3 (fr) Modification de la biosynthese de la lignine
WO2003087054A3 (fr) Methodes d'identification de composes modulant l'activite enzymatique
WO2006078984A3 (fr) Utilisations de derives de methylphenidate
WO2007089743A3 (fr) Inhibiteurs du canal potassique
WO2004043400A3 (fr) Promedicaments actives par peptide deformylase
WO2007089679A3 (fr) Inhibiteurs du canal potassique
WO2007117961A3 (fr) Inhibiteurs de la rénine
WO2009040755A3 (fr) Composés du pyrrole en tant qu'inhibiteurs de mycobactéries, leur synthèse et intermédiaires de cette synthèse
WO2007089678A3 (fr) Inhibiteurs du canal potassique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764176

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08764176

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP